These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 36781852)

  • 21. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
    Koikawa K; Kibe S; Suizu F; Sekino N; Kim N; Manz TD; Pinch BJ; Akshinthala D; Verma A; Gaglia G; Nezu Y; Ke S; Qiu C; Ohuchida K; Oda Y; Lee TH; Wegiel B; Clohessy JG; London N; Santagata S; Wulf GM; Hidalgo M; Muthuswamy SK; Nakamura M; Gray NS; Zhou XZ; Lu KP
    Cell; 2021 Sep; 184(18):4753-4771.e27. PubMed ID: 34388391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma.
    Somani VK; Zhang D; Dodhiawala PB; Lander VE; Liu X; Kang LI; Chen HP; Knolhoff BL; Li L; Grierson PM; Ruzinova MB; DeNardo DG; Lim KH
    Gastroenterology; 2022 Jun; 162(7):2047-2062. PubMed ID: 35271824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological Gene Signature Associated With the Tumor Microenvironment of Pancreatic Cancer After Neoadjuvant Chemotherapy.
    Hane Y; Tsuchikawa T; Nakamura T; Hatanaka KC; Saito T; Tanaka K; Nakanishi Y; Asano T; Noji T; Okamura K; Shichinohe T; Yokota I; Hatanaka Y; Hirano S
    Pancreas; 2020 Oct; 49(9):1240-1245. PubMed ID: 32898010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global targetome analysis reveals critical role of miR-29a in pancreatic stellate cell mediated regulation of PDAC tumor microenvironment.
    Dey S; Liu S; Factora TD; Taleb S; Riverahernandez P; Udari L; Zhong X; Wan J; Kota J
    BMC Cancer; 2020 Jul; 20(1):651. PubMed ID: 32660466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1.
    Zhang Z; Song B; Wei H; Liu Y; Zhang W; Yang Y; Sun B
    Drug Resist Updat; 2024 Mar; 73():101040. PubMed ID: 38228036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment.
    Carpenter ES; Kadiyala P; Elhossiny AM; Kemp SB; Li J; Steele NG; Nicolle R; Nwosu ZC; Freeman J; Dai H; Paglia D; Du W; Donahue K; Morales J; Medina-Cabrera PI; Bonilla ME; Harris L; The S; Gunchick V; Peterson N; Brown K; Mattea M; Espinoza CE; McGue J; Kabala SM; Baliira RK; Renollet NM; Mooney AG; Liu J; Bhalla S; Farida JP; Ko C; Machicado JD; Kwon RS; Wamsteker EJ; Schulman A; Anderson MA; Law R; Prabhu A; Coulombe PA; Rao A; Frankel TL; Bednar F; Shi J; Sahai V; Pasca Di Magliano M
    Clin Cancer Res; 2024 Jun; 30(11):2497-2513. PubMed ID: 37851080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
    Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
    [No Abstract]   [Full Text] [Related]  

  • 29. Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.
    Sinha M; Betts C; Zhang L; Griffith MJ; Solman I; Chen B; Liu E; Tamaki W; Stultz J; Marquez J; Sivagnanam S; Cheung A; Pener D; Fahlman A; Taber E; Lerner K; Crocker M; Todd K; Rajagopalan B; Ware C; Bridge M; Vo J; Dragomanovich H; Sudduth-Klinger J; Vaccaro G; Lopez CD; Tempero M; Coussens LM; Fong L
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression.
    Chen K; Wang Q; Li M; Guo H; Liu W; Wang F; Tian X; Yang Y
    EBioMedicine; 2021 Apr; 66():103315. PubMed ID: 33819739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer.
    Huang H; Brekken RA
    Am J Physiol Cell Physiol; 2020 Aug; 319(2):C233-C243. PubMed ID: 32432930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single cell RNA-seq reveals the CCL5/SDC1 receptor-ligand interaction between T cells and tumor cells in pancreatic cancer.
    Chen K; Wang Y; Hou Y; Wang Q; Long D; Liu X; Tian X; Yang Y
    Cancer Lett; 2022 Oct; 545():215834. PubMed ID: 35917973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy.
    Yang D; Sun X; Moniruzzaman R; Wang H; Citu C; Zhao Z; Wistuba II; Wang H; Maitra A; Chen Y
    Gastroenterology; 2024 Jul; 167(2):298-314. PubMed ID: 38467382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated transcriptional analysis reveals macrophage heterogeneity and macrophage-tumor cell interactions in the progression of pancreatic ductal adenocarcinoma.
    Yang K; Yang T; Yu J; Li F; Zhao X
    BMC Cancer; 2023 Mar; 23(1):199. PubMed ID: 36864399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies.
    Lee JJ; Bernard V; Semaan A; Monberg ME; Huang J; Stephens BM; Lin D; Rajapakshe KI; Weston BR; Bhutani MS; Haymaker CL; Bernatchez C; Taniguchi CM; Maitra A; Guerrero PA
    Clin Cancer Res; 2021 Nov; 27(21):5912-5921. PubMed ID: 34426439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.
    Ng CF; Glaspy J; Placencio-Hickok VR; Thomassian S; Gong J; Osipov A; Hendifar AE; Moshayedi N
    J Natl Compr Canc Netw; 2022 Oct; 20(10):1076-1079. PubMed ID: 36240849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
    Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
    Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis.
    Hu LP; Zhang XX; Jiang SH; Tao LY; Li Q; Zhu LL; Yang MW; Huo YM; Jiang YS; Tian GA; Cao XY; Zhang YL; Yang Q; Yang XM; Wang YH; Li J; Xiao GG; Sun YW; Zhang ZG
    Clin Cancer Res; 2019 Feb; 25(4):1318-1330. PubMed ID: 30420446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma.
    Satoh K; Hamada S; Shimosegawa T
    J Gastroenterol; 2015 Feb; 50(2):140-6. PubMed ID: 25216997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
    Takeuchi S; Baghdadi M; Tsuchikawa T; Wada H; Nakamura T; Abe H; Nakanishi S; Usui Y; Higuchi K; Takahashi M; Inoko K; Sato S; Takano H; Shichinohe T; Seino K; Hirano S
    Cancer Res; 2015 Jul; 75(13):2629-40. PubMed ID: 25952647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.